Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 17/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6904110 | 0.99 | TACR1 (0.35) | TACR1 | |
| Hydrochloric Acid SCHEMBL6904903 | 0.88 | TACR1 (0.35) | TACR1 | |
| Hydrochloric Acid SCHEMBL6903202 | 0.78 | TACR1 (0.40) | TACR1 | |
| SCHEMBL7060115 | 0.78 | TACR1 (0.38) | TACR1 | |
| SCHEMBL6903445 | 0.78 | TACR1 (0.38) | TACR1 | |
| SCHEMBL7060120 | 0.78 | TACR1 (0.38) | TACR1 | |
| Hydrochloric Acid SCHEMBL6906073 | 0.78 | TACR1 (0.39) | TACR1 | |
| SCHEMBL6903170 | 0.76 | TACR1 (0.39) | TACR1 | |
| Hydrochloric Acid SCHEMBL7060852 | 0.75 | TACR1 (0.42) | TACR1 | |
| Hydrochloric Acid SCHEMBL7059890 | 0.75 | TACR1 (0.43) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-04 | — | — | US | claimed |
| JP-2004517873-A | — | — | 2004-06-17 | — | — | JP | claimed |
| EP-1368343-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | claimed |
| WO-2002055518-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | BDKRB1, BDKRB2, TACR1 | TACR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.